Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOREA: Lorlatinib in Untreated ALK-Positive NSCLC
NCT06487078Recruiting
- Sponsor
- Pfizer
- Start
- Jan 2025
- Primary completion
- Nov 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of lorlatinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoint: Progression-Free Survival at 25 months. Started Jan 2025; status: recruiting.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06487078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06487078.